News Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
22.48 ^USD	-2.26%		-2.26%	-30.79%

Apr. 22	Corcept Therapeutics Incorporated Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing?s Syndrome	CI
Apr. 15	Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call	Apr. 24	GL
Corcept Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing's syndrome	Apr. 23	AQ
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome	Apr. 22	GL
Corcept Therapeutics Incorporated Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing?s Syndrome	Apr. 22	CI
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)	Apr. 15	GL
Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis	Apr. 15	CI
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer	Apr. 08	GL
Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer	Apr. 08	CI
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome	Apr. 01	GL
Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome	Apr. 01	CI
Corcept Therapeutics Insider Sold Shares Worth $430,475, According to a Recent SEC Filing	Mar. 21	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	Feb. 16	MT
Truist Securities Adjusts Price Target on Corcept Therapeutics to $42 From $36, Maintains Buy Rating	Feb. 16	MT
Sector Update: Health Care Stocks Gain Pre-Bell Friday	Feb. 16	MT
Corcept Therapeutics Q4 Net Income, Revenue Increase; Reiterates Guidance; Shares Gain Pre-Bell	Feb. 16	MT
Sector Update: Health Care	Feb. 16	MT
Corcept Therapeutics Q4 Net Income, Revenue Increase; Reiterates Guidance	Feb. 15	MT
Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024	Feb. 15	CI
Transcript : Corcept Therapeutics Incorporated, Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Corcept: Q4 Earnings Snapshot	Feb. 15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Summary

Filters